Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck

Sati Akbaba, Andreas Möck, Juliane Hoerner‐Rieber, Thomas Held, Sonja Katayama, Tobias Förster, Christian Freudlsperger, Stefan Rieken, Klaus Herfarth, Peter K. Plinkert, Jürgen Debus, Sebastian AdebergFrontiers in Oncology 2019 · DOI

TL;DR

This study investigates a combined radiotherapy approach using intensity-modulated radiation therapy (IMRT) and a carbon ion boost for head and neck adenocarcinomas, a rare and challenging cancer. The findings suggest this bimodal treatment offers favorable local control and survival for salivary gland and salivary duct adenocarcinomas with manageable toxicity, though challenges remain for bilateral intestinal-type adenocarcinomas.

What Problem Does This Paper Address?

Adenocarcinomas of the head and neck are a diverse group of rare cancers with limited established treatment guidelines due to a lack of extensive data. This heterogeneity in origin and histology makes it difficult to generalize treatment outcomes. The authors aim to address this by evaluating a specific, dose-escalated bimodal radiotherapy regimen – combining IMRT with an active raster-scanning carbon ion boost – for its effectiveness in local control (LC) and survival in patients with these challenging tumors. The rationale for carbon ion therapy stems from its higher biological effectiveness and more conformal dose delivery, which is crucial for treating radioresistant tumors in the sensitive head and neck region.

Methods

The study employed a retrospective analysis of 80 consecutive patients treated between 2009 and 2018. Patients received either postoperative or definitive radiotherapy. The core of the treatment involved a bimodal approach:

  • Intensity-Modulated Radiotherapy (IMRT): A base plan delivering 50-56 Gy in 2 Gy fractions to the clinical target volume (CTV2), which included the primary tumor or tumor bed and typical local/regional pathways.
  • Carbon Ion Boost: An active raster-scanning carbon ion boost delivering 18-24 Gy (RBE) in 3 Gy (RBE) single fractions to CTV1 (gross tumor volume or tumor bed).

Kaplan-Meier estimates were used to assess local control (LC), overall survival (OS), and progression-free survival (PFS). Prognostic factors were identified using log-rank tests and Cox regression modeling. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE).

Datasets

The study utilized patient records from 80 consecutive patients treated at the University Hospital Heidelberg and the Heidelberg Ion-Beam Therapy Center between 2009 and 2018. The data included patient demographics, tumor characteristics (histology, site, stage, differentiation, invasion), treatment details, and follow-up outcomes. No new datasets were introduced.

Key Insights and Ideas

  • Bimodal RT Shows Promise for Specific Subtypes: The combined IMRT and carbon ion boost approach appears to be a viable and effective strategy for salivary gland adenocarcinoma (SGAC) and salivary duct adenocarcinoma (SDAC), yielding good local control and survival rates.
  • ITACs Remain a Challenge: Despite dose escalation, bilateral intestinal-type adenocarcinomas (ITAC) demonstrated significantly poorer local control and a trend towards worse survival, highlighting their radioresistance and aggressive nature.
  • Bilateral Tumors are a Significant Negative Prognostic Factor: The presence of bilateral tumors, particularly in ITACs, was strongly associated with decreased local control, suggesting a need for tailored strategies for these cases.
  • Toxicity is Manageable: The bimodal treatment regimen was generally well-tolerated, with a manageable rate of acute and late toxicities, which is a critical consideration for head and neck radiotherapy.

Key Results

  • Overall Outcomes: With a median follow-up of 41 months, the 3-year Kaplan-Meier rates were 83% for LC, 74% for OS, and 60% for PFS.
  • Histology-Specific Outcomes:
    • SGAC and SDAC achieved a 3-year LC rate of 93%.
  • ITAC showed a significantly lower 3-year LC rate of 50% (p < 0.01) compared to SGAC/SDAC.
  • While not statistically significant, 3-year OS was 88% for SGAC, 78% for SDAC, and 67% for ITAC. Similarly, 3-year PFS was 72% for SGAC, 53% for SDAC, and 44% for ITAC.
  • Prognostic Factors:
    • Bilateral tumor side was an independent negative prognostic factor for LC (p < 0.01).
  • ITAC histology was associated with worse OS compared to SGAC (p = 0.024).
  • ECOG performance status 2 and N+ nodal classification were negative prognostic factors for OS.
  • Male gender, N+ nodal classification, and tumor inoperability were negative prognostic factors for PFS.
  • Toxicity: Acute grade ≥3 toxicities occurred in 21% of patients, and late grade ≥3 toxicities in 25%. Severe adverse events (grade 4) were rare.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature limits definitive conclusions and makes it challenging to compare postoperative versus primary RT.
  • Limited Patient Numbers per Subgroup: The rarity of these tumors means small patient numbers within each histological subgroup (SGAC, SDAC, ITAC) can affect the statistical power for subgroup comparisons.
  • Comparability with Literature: The variety of dose calculation models for carbon ion RT and the rarity of this treatment modality worldwide make direct comparisons with existing literature challenging.
  • Alternative Fractionation: The role of alternative fractionation schedules (e.g., accelerated RT) remains unclear due to missing data.

Future work could focus on prospective studies to validate these findings, explore optimal fractionation strategies, and develop more targeted approaches for challenging subtypes like bilateral ITACs. The authors also note the limited availability of carbon ion therapy globally, which restricts its widespread application.

Summary updated

Abstract

<b>Introduction:</b> Data regarding treatment and survival outcome of patients with adenocarcinoma of the head and neck are limited to case reports and case series. As a consequence of lacking evidence, treatment guidelines do not exist. We aimed to analyze the effect of a bimodal irradiation regime with intensity modulated radiotherapy (IMRT) and carbon ion boost on local control (LC) and survival in adenocarcinoma patients for a large patient collective. <b>Materials and Methods:</b> Patient records of eighty consecutive patients treated between 2009 and 2018 were analyzed retrospectively and Kaplan-Meier estimates for LC, overall survival (OS) and progression-free survival (PFS) were compared among patients with salivary gland adenocarcinoma (SGAC), salivary duct adenocarcinoma (SDAC), and intestinal-type adenocarcinoma (ITAC) according to the World Health Organization (WHO). Prognostic factors were identified using the log-rank test and cox-regression modeling. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). <b>Results:</b> Median follow-up was 41 months. The 3-year and estimated 5-year Kaplan-Meier rates for all patients were 83 and 75% for LC, 74 and 50% for OS and 60 and 53% for PFS, respectively. While bimodal RT for ITAC resulted in a significantly decreased 3-year LC rate of 50 vs. 93% for each SGAC and SDAC (<i>p</i> < 0.01), no statistical significant survival differences could be identified across the three groups regarding OS (<i>p</i> = 0.08) and PFS (<i>p</i> = 0.063). 3-year OS was 88% for SGAC, 78% for SDAC and 67% for ITAC and 3-year PFS was 72% for SGAC, 53% for SDAC and 44% for ITAC, respectively. Nevertheless, in subgroup analysis, OS for ITAC was significantly worse compared to SGAC (<i>p</i> = 0.024). In multivariate analysis, bilateral tumor side (vs. unilateral) solely could be identified as independent negative prognostic factor for LC (<i>p</i> < 0.01). Treatment was well-tolerated with 21% acute (<i>n</i> = 17) and 25% (<i>n</i> = 20) late grade ≥3 toxicities. <b>Conclusion:</b> Radiotherapy including active raster-scanning carbon ion boost for relatively radio resistant adenocarcinomas of the head and neck resulted in favorable survival outcome for salivary gland and salivary duct adenocarcinomas with moderate toxicity. However, local control and prognosis for bilateral intestinal-type adenocarcinomas (ITAC) seem to remain low even after dose-escalation.
BibTeX
@inproceedings{akbaba2019treatment,
  author = {Sati Akbaba and Andreas Möck and Juliane Hoerner‐Rieber and Thomas Held and Sonja Katayama and Tobias Förster and Christian Freudlsperger and Stefan Rieken and Klaus Herfarth and Peter K. Plinkert and Jürgen Debus and Sebastian Adeberg},
  title = {{Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck}},
  booktitle = {Frontiers in Oncology},
  year = {2019},
  doi = {10.3389/fonc.2019.00755},
}
Figure